19 July 2016
US drugs company Pfizer has entered into a manufacturing and licensing agreement with Russian pharmaceutical company NovaMedica.
Pfizer has proposed to invest in NovaMedica’s construction of a new manufacturing plant in the Kaluga region.
The technology for production of more than 30 medicinal products from Pfizer’s portfolio will also be licensed to the Russian company.
In a press release, Pfizer and NovaMedica announced that the design, development and construction of the manufacturing plant are scheduled to begin in 2016, with the start of medicine production planned for 2020.
Petra Weil, regional president of Europe from Pfizer, said: “We contribute broadly to the modernisation of the Russian pharmaceutical industry, education in medicine and high-quality manufacturing and bringing innovation in the field of medicine.”
Brian Dovey, member of the board of directors of NovaMedica, said: “The strategic partnership with Pfizer provides a major boost toward NovaMedica’s goal of becoming a world-class leader in the fast-growing Russian pharmaceutical market.”
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024
Russian drug for the treatment of viral hepatitis will be exempt from duty in Mongolia
24 April 2024
PM Mishustin: “We need to increase the production of vital and essential drugs in Russia”
24 April 2024